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Tumor necrosis factor (TNF) receptor-associated
factor 3 (TRAF3) functions downstream of multiple
TNF receptors and receptors that induce interferon-a
(IFN-a), IFN-b, and IFN-l production, including
Toll-like receptor 3 (TLR3), which is deficient in
some patients with herpes simplex virus-1 encepha-
litis (HSE). Mice lacking TRAF3 die in the neonatal
period, preventing direct investigation of the role of
TRAF3 in immune responses and host defenses
in vivo. Here, we report autosomal dominant, human
TRAF3 deficiency in a young adult with a history of
HSE in childhood. The TRAF3 mutant allele is loss-
of-expression, loss-of-function, dominant-negative
and associated with impaired, but not abolished,
TRAF3-dependent responses upon stimulation of
both TNF receptors and receptors that induce IFN
production. TRAF3 deficiency is associated with
a clinical phenotype limited to HSE resulting from
the impairment of TLR3-dependent induction of
IFN. Thus, TLR3-mediated immunity against primary
infection by HSV-1 in the central nervous system is
critically dependent on TRAF3.
INTRODUCTION
Herpes simplex virus 1 (HSV-1) encephalitis (HSE) is a devas-
tating infection of the central nervous system (CNS) (Whitley,400 Immunity 33, 400–411, September 24, 2010 ª2010 Elsevier Inc.2006). HSE is the most common form of sporadic viral encepha-
litis in Western countries, in which its incidence has been esti-
mated at approximately 1 to 2 in 250,000 individuals per year.
The disease peaks in childhood, between the ages of 3 months
and 6 years. During primary infection with HSV-1, the virus rea-
ches the CNS via a neurotropic route involving the trigeminal
and olfactory nerves (Abel et al., 2010; De Tiege et al., 2008).
Acyclovir treatment decreases the mortality rate in affected chil-
dren, but substantial neurological impairment is nevertheless
observed in most survivors and, in particular, in young children.
However, HSV-1 is widespread and typically innocuous in
human populations.
Childhood HSE was not associated with known immunodefi-
ciencies and the mechanism of its pathogenesis remained
elusive until we identified the first two genetic etiologies of
this condition: autosomal recessive UNC-93B deficiency, which
abolishes Toll-like receptor 3 (TLR3), TLR7, TLR8, and TLR9
signaling (Casrouge et al., 2006), and autosomal dominant
TLR3 deficiency, which specifically affects TLR3 signaling
(Zhang et al., 2007). These findings are consistent with the lack
of HSE in patients with IRAK-4 and MyD88 deficiencies because
these patients have nonfunctional TLR7, TLR8, and TLR9 but
a functional TLR3 (Picard et al., 2003; von Bernuth et al., 2008;
Yang et al., 2005).
Our previous demonstration that STAT1 deficiency, unlike
IFN-gR1 or IFN-gR2 deficiency, confers predisposition to
multiple viral diseases, including HSE, suggested that impair-
ment of the TLR3-dependent production of IFN-a and IFN-b
(type I IFN) and IFN-l (type III IFN) might account for HSE in
patients with TLR3 and UNC-93B deficiencies (Chapgier et al.,
2009; Dupuis et al., 2003). Collectively, these studies suggest
Figure 1. Heterozygous TRAF3 Mutation
in a Patient with HSE
(A) Family pedigree, with allele segregation. The
patient with HSE, in black, is heterozygous for
the mutation.
(B) Heterozygous c.352C > T mutation in patient 1
(P1). The sequence of the polymerase chain reac-
tion products of genomic DNA from leukocytes of
a control (C) and P1 is shown.
(C) Schematic representation of TRAF3 protein
structure. Human TRAF3 has eleven exons, en-
coding a protein composed of a ring finger and
five zinc-finger domains in the N-terminal region,
followed by an isoleucine zipper and a TRAF
domain in the C-terminal region. P1 carries the
c.352C > T mutation, which results in an arginine
(R) to tryptophan (W) substitution at amino acid
position 118 (R118W) in the first zinc-finger
domain.
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Human TRAF3 Deficiencythat childhood HSE may result from impaired type I and/or type
III IFN production in response to the stimulation of TLR3 by
dsRNA intermediates of HSV-1 in the CNS, in at least some
children. Because only a small fraction of children with HSE carry
mutations in the TLR3 and UNC-93B genes, we searched for
mutations in other genes controlling the TLR3 pathway. Here,
we report on an autosomal dominant deficiency of the TRAF3
adaptor protein in a patient with HSE. This experiment of
nature indicates that TLR3-mediated immunity against primary
infection by HSV-1 in the central nervous system is critically
dependent on TRAF3.
RESULTS
Heterozygous TRAF3 Mutation in a Patient with HSE
We investigated an 18-year-old French girl (P1) who had suffered
from HSE at the age of 4 years (Supplemental Information
available online) and carried no mutation in the coding region
ofUNC93B1 or TLR3, themRNAs of whichwere normally spliced
and generated in normal amounts. No mutations were found
in the coding regions of seven other genes known to control
the TLR3—type I IFN pathway, encoding Toll-IL-1 receptor
domain-containing adaptor protein-inducing IFN-b (TRIF),
TRAF family member-associated NF-kB activator (TANK), the
adaptor protein SINTBAD, NAK-associated protein-1 (NAP1),
TANK-binding kinase 1 (TBK1), Ik-B kinase-3 (IKK-3), and
the transcription factor interferon regulatory factor 3 (IRF-3).
A heterozygous substitution (C/T) was found at nucleotide
position 352 (c.352C > T) in exon 4 of the gene encoding TNF
receptor-associated factor 3 (TRAF3) (Bishop and Xie, 2007;
Hacker et al., 2006; He et al., 2007; Oganesyan et al., 2006) in
genomic DNA (gDNA) from the granulocytes, EBV-transformed
B cells (EBV-B cells), and SV40-transformed fibroblasts (SV40-Immunity 33, 400–411, Sefibroblasts) of P1 (Figures 1A and B). No
other mutations were found in the coding
region of TRAF3. The TRAF3 mutation
is missense and nonconservative, as it
replaces an Arg residue at position 118
in the first of the five zinc-finger domainswith a Trp residue (R118W) (Figure 1C). R118W was not found in
the NCBI and Ensembl databases or in up to 1,209 unrelated
healthy individuals (2,418 chromosomes) (including 1,050
healthy individuals from the CEPH-Human Genome Diversity
panel) examined, including 289 Europeans, ruling out an irrele-
vant polymorphism. The father, mother, and brothers of P1 do
not carry the R118W mutation. Alignment of the human TRAF3
sequence with sequences from the 13 animal species in which
TRAF3 has been sequenced showed R118 to be strictly
conserved throughout evolution (Figure S1). These data suggest
that the de novo R118W germline mutation in TRAF3 may
be responsible for the autosomal dominant predisposition to
HSE in P1.
Impaired TRAF3 Production in Cells from the Patient
We then assessed the expression of TRAF3mRNA and protein in
cells from P1. Quantitative PCR showed baseline TRAF3 mRNA
expression in SV40-fibroblasts (human fibroblasts immortalized
with SV40) (Figure 2A) and EBV-B cells (human B cells immortal-
ized with EBV) (Figure S2A) from P1 to be normal. The wild-type
(WT) andmutantTRAF3alleleswere expressed to similar extents,
as shown by direct sequencing of the RT-PCR product (data not
shown). Incontrast, TRAF3protein inSV40-fibroblasts (Figure2A)
and EBV-B cells (Figure S2B) from P1 were only about 17.5%
those in five unrelated healthy controls (data not shown), as
shown by immunoblot analysis. Similar results were obtained
with two additional antibodies recognizing different TRAF3 epi-
topes at some distance from residue 118 (Figure S2C). The
R118W mutation, therefore, seems to prevent stable TRAF3
protein production. It also seems to have an effect on the amount
of WT protein generated from the other allele. We stably trans-
fected a TRAF3 knockdown RAW mouse macrophage cell line
(RAW Traf3/) (Tseng et al., 2010) with vectors encoding theptember 24, 2010 ª2010 Elsevier Inc. 401
Figure 2. TRAF3 Expression Levels and TLR3 Response of a Child with HSE
(A) Top: TRAF3 mRNA expression in SV40-fibroblasts from a control (C) and P1. b-glucuronidase (GUS) was used for normalization. Bottom: Representative
immunoblot analysis of TRAF3 in SV40-fibroblasts from a control (C) and P1. TRAF3 (%) indicates densitometry results, normalized with respect to GADPH
and expressed as a percentage of control TRAF3. The control is a representative example of the five controls analyzed.
(B) Top: TRAF3 mRNA levels normalized with respect to 18S rRNA and (bottom) immunoblot analysis of TRAF3 in RAW cells and RAW Traf3/ cells not
transfected and stably transfectedwith humanwild-type (WT) (pWPI-TRAF3) or R118Wmutant TRAF3 (pBABE-TRAF3-R118W) constructs. As a negative control,
we transfected cells with a mock WT vector (Mock-1, pWPI) or with a mock R118W mutant vector (Mock-2, pBABE). TRAF3 (%) indicates densitometry results
normalized with respect to GADPH amounts and expressed as a percentage of TRAF3 amounts in RAW cells.
(C) Production of IFN-b (measured in structural units, IU/ml), IFN-l, and IL-6 by SV40-fibroblasts after poly(I:C) stimulation (25 mg/ml), at various time points
(left panels) and for various doses of poly(I:C), for 24 hr (right panels), as assessed by ELISA. C is the positive control and P1 is patient 1; UNC93B1/ is the
UNC-93B-deficient patient.
(D) NF-kB ELISA of nuclear extracts from SV40-fibroblasts from a control (C), P1, and a NEMO-deficient patient (negative control), after stimulation with TNF-a
and IL-1b for 30 min, or stimulation with poly(I:C) for 120 min.
(E) IRF-3 monomers and dimers in total cell extracts of SV40-fibroblasts from a control (C) and P1, after stimulation with poly(I:C) for 1 and 2 hr, as assessed by
immunoblot. TLR3- and UNC-93B-deficient patients were used as negative controls.
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Human TRAF3 DeficiencyWT or R118W human TRAF3 allele. TRAF3 protein was detected
after transfectionwith theWTconstruct, but not after transfection
with the mock vector or the R118W allele, whereas mRNA was
detected for both the WT and R118W forms (Figure 2B).
Impaired TLR3 Responsiveness of the Patient’s
Fibroblasts
The induction of IFN-b and, subsequently, of IFN-inducible
target genes in response to TLR3 agonists is markedly impaired
in bone marrow-derived macrophages (BMMs) generated from
irradiated C57BL/6 mice, reconstituted with Traf3/ fetal liver402 Immunity 33, 400–411, September 24, 2010 ª2010 Elsevier Inc.cells (Hacker et al., 2006; Oganesyan et al., 2006). We investi-
gated the contribution of TRAF3 deficiency to the pathogenesis
of HSE in P1 by evaluating the TLR3 pathway in SV40-trans-
formed dermal fibroblasts in which the response to poly(I:C) is
TLR3-dependent (Casrouge et al., 2006; Zhang et al., 2007).
In control SV40-fibroblasts, IFN-b, IFN-l, and IL-6 were secreted
in a time- and dose-dependent manner, after TLR3 stimulation
with poly(I:C) (Figure 2C). In contrast, cells from P1 and from
an UNC-93B-deficient patient did not respond. TNF-a-induced
IL-6 production was normal, indicating that the differences in
IFN-b, IFN-l, and IL-6 production upon TLR3 stimulation were
Figure 3. Complementation of the Patient’s Cells and Dominant-Negative Effect
(A) Immunoblot analysis of TRAF3 amounts in SV40-fibroblasts from a control (C) and P1, not transfected (P1) and stably transfected with human WT TRAF3
(P1 WT) or mock vector (P1-mock), with and without stimulation with poly(I:C) for 24 hr. TRAF3 (%) indicates densitometry results normalized with respect to
GADPH amounts and expressed as a percentage of control TRAF3 amounts.
(B) Production of IFN-b and IL-6, as assessed by ELISA, in SV40-fibroblasts from a control (C), P1, an UNC-93B-deficient patient (UNC93B/), P1 cells
transfected with human WT TRAF3 (P1-WT), or mock vector (P1-mock).
(C) Immunoblot analysis of TRAF3 amounts in RAW cells, nontransfected RAW Traf3/ cells, and RAW cells stably transfected with R118W mutant TRAF3
(R118W), WT TRAF3 (WT), or mock vector (Mock).
(D) IFN-b production, as assessed by ELISA, in RAW cells, not transfected or transfected with R118Wmutant TRAF3 or mock vector. All transfections generated
stable cell lines. Glyceraldehyde phosphate dehydrogenase (GADPH) was used as an internal expression control forWB. The panels illustrate results from a single
experiment, representative of three. Mean values ± SD were calculated from three independent experiments.
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Human TRAF3 Deficiencynot because of a general nonresponsiveness of the cells (Fig-
ure S2D). Similar results were obtained for the IFN-b and IFN-l
mRNAs (Figure S2E) and for analyses of primary dermal
fibroblasts (data not shown).
We dissected the cellular phenotype of P1 further by studying
two transcription factors controlling the TLR3-IFN pathway:
NF-kB and IRF-3. Accumulation of the NF-kB p65 subunit in
the nucleus in response to poly(I:C) was impaired in P1, as
shown by ELISA (Figure 2D), whereas the response to both
TNF-a and IL-1b was normal. In contrast, the dimerization of
IRF-3 in response to poly(I:C) in SV40-fibroblasts from P1 was
less strongly affected, as shown by comparison with healthy
controls and with TLR3-deficient and UNC-93B-deficient cells
(Figure 2E) (Casrouge et al., 2006; Zhang et al., 2007). The
TRAF3 deficiency, therefore, affected the TLR3 pathway, in
terms of the activation of NF-kB and, to a lesser extent, IRF-3.
This resulted in the impairment of cytokine production, with the
abolition of IFN-b, IFN-l, and IL-6 induction by poly(I:C), in
particular.
Complementation of the Patient’s Cells with Wild-Type
TRAF3
P1 fibroblasts were transfected withWT TRAF3 and stable trans-
fectants were obtained (Figure 3A). These cells contained no
more than about 30% the amount of TRAF3 present in healthy
controls. However, they contained more TRAF3 than nontrans-
fected and mock-transfected P1 cells, which contained only
about 17.5% the amount of TRAF3 present in controls (Fig-Imure 3A), consistent with the mutant allele being structurally
dominant-negative. Nevertheless, stable transfection with the
WT TRAF3 allele, unlike mock transfection, complemented the
defect in the TLR3-dependent induction of IFN-b, IL-6 (Fig-
ure 3B), and IFN-l (Figure S3A), indicating that the doubling of
TRAF3 amounts, although modest, was sufficient to overcome
the functional defect. No complementation of the phenotype
was observed after transfection with R118W TRAF3 (Figures
S3B and S3C). Thus, the WT TRAF3 allele complemented the
lack of response to TLR3 in P1 fibroblasts, strongly suggesting
that the patient’s fibroblastic phenotype and, by inference from
TLR3 and UNC-93B deficiencies (Casrouge et al., 2006; Zhang
et al., 2007), the patient’s clinical phenotype of HSE, resulted
from TRAF3 deficiency.
The TRAF3Mutant Allele Is Dominant-Negative
The WT TRAF3 allele conferred functional complementation of
cells from P1, but TRAF3 protein levels remained lower (30%)
than those in the cells of all healthy controls tested. This finding
is consistent with the much lower than expected amounts of
TRAF3 in the heterozygous cells of P1 (17.5%). Thus, although
the R118W allele is a loss-of-expression allele, it may exert
a dominant-negative effect by destabilizing proteins produced
from the WT allele. Mouse RAW macrophages were used to
test this hypothesis, because human andmouse TRAF3 proteins
are 97% identical and the antibodies recognizing human TRAF3
also recognize its mouse ortholog. The amounts of mouse
TRAF3 in RAW cells stably transfected with human R118Wmunity 33, 400–411, September 24, 2010 ª2010 Elsevier Inc. 403
Figure 4. SV40-Fibroblast Studies: Production of Type I IFN and Cytokines
(A) Production of IFN-b, IFN-l, and IL-6 after stimulation with VSV, as assessed by ELISA, in SV40-fibroblasts from a control (C), P1, and an UNC-93B-deficient
patient (UNC93B1/).
(B) Viable cell percentages, estimated by resazurin oxidation/reduction, for SV40-fibroblasts from a healthy control (C), P1, TLR3+/,UNC93B1/, and STAT1/
patients, 24 hr after infection with VSV, at various multiplicities of infection. The cells were either not treated (left panel) or were subjected to prior treatment
(right panel) with recombinant IFN-a for 18 hr.
(C) VSV titers, estimated on Vero cells, in SV40 fibroblasts from a healthy control (C), P1, STAT1/, UNC93B1/, and TLR3+/ patients, at various times after
VSV infection without (left panel) or with (right panel) 18 hr of pretreatment with IFN-a2b.
(D) The production of IFN-b and IL-6, assessed by ELISA, in SV40-fibroblasts from a control (C), P1,UNC93B1/, or P1 SV40 fibroblasts transfected with human
WT TRAF3 (P1-WT) or mock vector (P1-mock).
(E) Viable cell percentages, estimated by resazurin oxidation and reduction, for SV40 fibroblasts from a healthy control (C), P1, P1 cells transfected with WT
TRAF3 (P1-WT), and P1 cells transfected with mock vector (P1-mock), 24 hr after infection with VSV, at various multiplicities of infection. The cells were either
not treated (left panel) or subjected to prior treatment (right panel) with recombinant IFN-a2b for 18 hr.
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Human TRAF3 DeficiencyTRAF3were only about 50% those in nontransfected RAW cells,
mock-transfected cells, or cells transfected with human WT
TRAF3 (Figure 3C). Similar results were obtained in transient
transfection experiments (data not shown). However, this had
no functional consequence because IFN-b production after
stimulation with poly(I:C) was normal, implying that the small
amount of protein produced was nonetheless sufficient to
activate the TLR3 pathway (Figure 3D), a finding consistent
with the successful complementation of the patient’s cells by
only about 30% the amount ofWT human TRAF3 generally found
in normal cells (Figure 3A). Similar results were obtained when
SV40 fibroblasts were stably transfected with the same vectors
(Figures S3D and S3E). Moreover, transient transfections of
RAW Traf3/ cells showed the R118W mutant form to have a
dominant-negative effect. In cells cotransfected with a 1:1 ratio
of WT TRAF3 and mock vector or R118W TRAF3, we found
that TRAF3 protein expression was 30% lower in the presence
of the mutant form (Figure S4A). The cotransfection of cells
with different ratios of WT:R118W TRAF3 showed that TRAF3
protein expression decreased as the proportion of the mutant
form increased (Figure S4A). Moreover, cotransfection with
a fixed amount of WT TRAF3 and increasing amounts of mutant
TRAF3 confirmed the negative dominance by revealing a dose-
dependent impact of the mutant allele, in terms of TRAF3
expression (Figure S4A).
We further investigated the possible effect of the mutant form
on the stability of trimer formation by generating TRAF3 deletion
constructs without the C-terminal region implicated in trimer
assembly. The deletion of this region from both the WT and
R118W forms had no effect on TRAF3 expression in RAW
Traf3/ cells cotransfected with the wild-type and deletion
constructs (Figure S4A). Similar results were obtained after the
cotransfection of cells with the WT construct and other shorter
deletions of TRAF3 (data not shown). The dominant-negative
effect of the R118W allele probably resulted from the inhibition
of TRAF3 trimer formation (Pullen et al., 1999) because the
patient’s TRAF3 expression (17.5%) was close to the expected
frequency of homotrimers composed of WT subunits only
(12.5%) (Figure S4B). Unstable heterotrimers may be more
susceptible to protein degradation, resulting in the persistence
within cells of only the remaining stable homotrimers. Thus, the
R118W TRAF3 allele exerts a dominant-negative effect in various
types of mouse and human cells by decreasing production of
the WT protein, thus accounting for the much lower total amount
of TRAF3 present and the profound impairment of TLR3
responses in cells from this heterozygous patient.
Impaired IFN-Dependent Control of Viruses
in TRAF3-Deficient Fibroblasts
We studied fibroblast responses to vesicular stomatitis virus
(VSV) infection, which have been shown to be impaired in
UNC-93B-deficient and TLR3-deficient patients (Casrouge
et al., 2006; Zhang et al., 2007). IFN-b, IFN-l, and IL-6 were
produced in smaller amounts by P1 and UNC-93B-deficient
SV40-fibroblasts than by control cells (Figure 4A). The survival(F) VSV titers, estimated on Vero cells, in SV40-fibroblasts from a healthy control (C
at various times after VSV infection, without (left panel) or with (right panel) 18
independent experiments.
Imof the patient’s SV40-fibroblasts was found to bemarkedly lower
than that of control cells, after 24 hr of VSV infection (Figure 4B).
P1 cells behaved like the cells of patients with TLR3, UNC-93B,
and STAT1 deficiencies (Casrouge et al., 2006; Chapgier et al.,
2009; Zhang et al., 2007). Treatment with exogenous IFN-a2b
complemented the phenotype of TRAF3-deficient, TLR3-defi-
cient, and UNC-93B-deficient cells, but not that of STAT1-
deficient cells (Figure 4B). We also showed that control cells
contain VSV replication, whereas cells from P1 and from
patients with STAT1, UNC-93B, and TLR3 deficiencies did not
(Figure 4C). When cells from P1, UNC-93B-deficient, and
TLR3-deficient patients were subjected to prior treatment with
IFN-a2b, complementation was observed, as viral replication
was contained; no such complementation was observed for
STAT1-deficient cells (Figure 4C). Finally, we attempted to
complement the TRAF3 deficiency in these assays of cytokine
production, viral replication, and cell death. The production of
IFN-b, IFN-l and IL-6, cell survival, and viral replication in
response to viral infection were restored in P1 cells stably
transfected with the WT construct, but not in cells transfected
with the mutant human TRAF3 allele or the mock vector (Fig-
ures 4D–4F and Figures S3A and S3C). Thus, P1 cells display
impaired IFN-b production in response to VSV infection, resulting
in higher viral replication and cell death, and this phenotype,
which is also common to UNC-93B-deficient and TLR3-deficient
cells, results from TRAF3 deficiency. These findings identify
TRAF3 deficiency as a genetic etiology of HSE, causing disrup-
tion of the TLR3-dependent induction of anti-viral type I IFN and
IFN-l.
Impact of TRAF3 Deficiency on Other IFN-Inducing
Pathways
We also analyzed the impact of TRAF3 deficiency on other
pathways, starting with the antiviral pathways inducing type I
IFN and IFN-l (Bishop and Xie, 2007; He et al., 2007). Previous
studies established a role for TRAF3 in the TLR4, TLR7-TLR8
(Hacker et al., 2006; Hoebe and Beutler, 2006; Oganesyan
et al., 2006), and RIG-I and MDA-5 pathways (Michallet et al.,
2008). After the activation of TLR4 (LPS) and TLR7-TLR8
(R-848), monocyte-derived dendritic cells (MDDCs) from P1
produced smaller amounts of IFN-a, IL-12p40 (Figure 5A),
TNF-a, IL-6, and IL-10 (Figure S5A) than cells from eight control
subjects. Similar results were obtained after the activation of
TLR4 and TLR7-TLR8 in monocyte-derived macrophages
(MDMs), in terms of the production of IFN-l, IL-12p40 (Fig-
ure 5B), TNF-a, and IL-6 (Figure S5B). TRAF3 is also involved
in the RIG-I and MDA-5 pathway. We, therefore, tested this
pathway in SV40-fibroblasts. After activation with poly(I:C) plus
Lipofectamine or in vitro transcribed 50PPP-ssRNA (7sk-as), the
amounts of secreted IFN-b, IFN-l, and IL-6 were lower than
those of control cells, UNC-93B-deficient cells (Figure 5C), and
P1 SV40-fibroblasts transfected with WT TRAF3 (Figure S5C).
Poly(I:C) plus Lipofectamine is known to activate both the
RIG-I and MDA-5 pathways, whereas in vitro transcribed
50PPP-ssRNA (7sk-as) has been shown to be a RIG-I-specific), P1, P1 cells transfected withWT TRAF3 (P1-WT), or mock vector (P1-mock),
hr of pretreatment with IFN-a. Mean values ± SD were calculated from three
munity 33, 400–411, September 24, 2010 ª2010 Elsevier Inc. 405
Figure 5. Production of Type I IFN and
Cytokines in Immune System Cells
(A) Production of IFN-a and IL-12p40 after stimula-
tion with LPS and R-848, as assessed by ELISA, in
MDDCs. C is the positive control (one of the eight
controls tested) and P1 is patient 1.
(B) Production of IFN-l and IL-12p40 after stimula-
tion with LPS and R-848, as assessed by ELISA, in
MDMs. C is the positive control (one of the eight
controls tested) and P1 is patient 1.
(C) Production of IFN-b, IFN-l, and IL-6, as
assessed by ELISA, in SV40-fibroblasts after
stimulation with poly(I:C)+Lipofectamine or 7sk-
as. C is the positive control and P1 is patient 1;
UNC93B1/ is an UNC-93B-deficient patient.
(D) IFN-a production after stimulation with poly
(I:C) and various viruses, as assessed by ELISA,
in PBMCs. C is the positive control and P1 is
patient 1. The panel illustrates results from a single
experiment, representative of two.
(E) Production of IFN-b and IFN-l, as assessed
by ELISA, in SV40-fibroblasts after stimulation
with HSV-1. C is the positive control and P1 is
patient 1; UNC93B1/ is an UNC-93B-deficient
patient. Mean values ± SD were calculated from
three independent experiments.
(F) Production of IFN-b and IFN-l, as assessed by
ELISA, in SV40-fibroblasts, after stimulation with
various viruses. C is the positive control and P1 is
patient 1; UNC93B1/, TLR3+/, and MYD88/
are patients with the corresponding genotypes.
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Human TRAF3 Deficiencyagonist (Pichlmair et al., 2006). These pathways—the RIG-I
pathway in particular—are, therefore, apparently TRAF3 depen-
dent in human dermal fibroblasts. Finally, we assessed the over-
all impact of TRAF3 deficiency on the production of type I IFN
and IFN-l by investigating the response to several viruses in
various cell types. After 40 hr of stimulation, peripheral blood
mononuclear cells (PBMCs) from P1 produced IFN-a
(Figure 5D) and IL-6, IL-10, and IL-12p40 (Figures S5D–S5F) in
response to the ten viruses tested, in amounts similar to or
smaller than those produced by control cells. We investigated
the production of IFN-b and IFN-l in SV40-fibroblasts, after
stimulation with HSV-1 (Figure 5E) and with four other viruses
(VSV, para-III, Sindbis virus, and EMCV) (Figure 5F). P1 fibro-
blasts had a broader phenotype than cells from healthy controls,
UNC-93B-deficient, TLR3-deficient, and MyD88-deficient
patients. Thus, TRAF3 deficiency in the patient broadly affected
type I and type III IFN- inducing pathways.
Impact of TRAF3 Deficiency on TNFR Pathways
TRAF3 was initially shown to interact with various TNFRs, such
as CD40, LT-bR, and BAFFR, in particular (Bishop and Xie, 2007;
He et al., 2007). It was subsequently found to operate down-
stream from these receptors as a negative regulator of the alter-
native NF-kB pathway (He et al., 2006; Vallabhapurapu et al.,
2008; Zarnegar et al., 2008). We first analyzed the CD40
pathway (Cheng et al., 1995; Graham et al., 2009). P1 MDDC406 Immunity 33, 400–411, September 24, 2010 ª2010 Elsevier Inc.showed impaired production of IL-6 and IL-12p40 after CD40L
activation (Figures 6A and B). We also activated fresh B cells
from P1 (who has normal counts of the main circulating B cell
subsets, as defined by IgM and CD27 expression) with CD40L
and IL-4 and observed an impairment of proliferation and Ig
class switch recombination to IgE (data not shown). When
EBV-B cells from P1 were activated with CD40L, the p52
product was generated without stimulation and was, therefore,
constitutively activated, whereas p52 activation was not
constitutive in healthy controls (Figure S6A). CD40-deficient
cells served as negative controls (Conley et al., 2009). TRAF3
is also involved in the lymphotoxin-b receptor (LTbR) pathway
in humans and mice, inducing caspase-3-independent cell
death and IL-8 production (Chen et al., 2003; Kuai et al.,
2003). P1 SV40-fibroblasts displayed lower amounts of cell
death than control cells (Figure 6C) or P1 cells transfected
with WT-TRAF3 (Figure S6B) after LT-a1b2 stimulation. More-
over, P1 cells produced smaller amounts of IL-8 than control
cells and P1 SV40-fibroblasts transfected with WT-TRAF3
(P1-WT) (Figure 6D).
TRAF3 also controls IL-10 production in response to B cell-
activating factor receptor (BAFF-R) activation in human and
mouse cell lines (Gardam et al., 2008; Sasaki et al., 2008; Xu
and Shu, 2002). After the activation of BAFF in EBV-B cells, the
p52 product was generated without stimulation (i.e., it was
constitutively activated) in cells from P1, but not in cells from
Figure 6. TRAF3 in TNFR Pathways
(A and B) The production of IL-6 (A) and IL-12p40 (B) was assessed by ELISA in MDDC, after 24 hr of incubation with L-cells transfected with human CD40L
(CD40L) and nontransfected L-cells (Neg control), for a healthy control (C) and P1.
(C) Cell death assay, based on resazurin oxidation/reduction, for SV40-fibroblasts from a healthy control (C) and P1 treated with various doses of LTa1b2, with or
without IFN-g (80 IU/ml) for 72 hr.
(D) IL-8 production, assessed by ELISA, in SV40-fibroblasts from control (C), P1, P1 cells transfected with humanWT TRAF3 (P1-WT) or mock vector (P1-mock),
after activation with LTa1b2 at the concentration indicated.
(E)WB analysis of the p52 subunit in EBV-B cells not stimulated (NS) or stimulated with BAFF at a concentration of 100 ng/ml (BAFF). C is the positive control, P1 is
patient 1, andBAFFR/ is EBV-B cells from aBAFFR-deficient patient. ‘‘Fold induction’’ indicates densitometry results normalizedwith respect toGADPH levels,
expressed as a fold induction over nonstimulated control cells. GADPH was used as an internal control for WB. The panel illustrates results from a single exper-
iment, representative of three.
(F) IL-10 production, assessed by ELISA, in EBV-B cells, after BAFF activation (100 ng/ml). C is the positive control; P1 is patient 1, and BAFFR/ is a
BAFFR-deficient patient. Mean values ± SD were calculated from three independent experiments.
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tion in EBV-B cells showed that P1 cells produced more IL-10
than control cells and that this IL-10 production was not depen-
dent on BAFF activation (Figure 6F). BAFF-R-deficient EBV-B
cells were used as negative controls (Warnatz et al., 2009).
We conclude that TRAF3 deficiency in P1 affects at least theImCD40, LTbR, and BAFF-R pathways, as previously shown in
mouse and human cell lines. The lack of a corresponding overt
clinical phenotype is consistent with an incomplete functional
defect. By contrast, complete defects in CD40 (Conley et al.,
2009) and, to a lesser extent, BAFF-R (Warnatz et al., 2009),
have been shown to have clinical consequences. We wouldmunity 33, 400–411, September 24, 2010 ª2010 Elsevier Inc. 407
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tion to disease occurs to vary between pathways.
DISCUSSION
Wehave identified a patient with a heterozygous de novo R118W
germline mutation in TRAF3. Previous studies have identified
the R118W mutation of TRAF3 as a somatic mutation involved
in multiple myeloma (Annunziata et al., 2007; Keats et al.,
2007), independently indicating that this allele is deleterious
and suggesting that our patient might be at risk of this disease.
Heterozygosity for the R118W TRAF3 allele leads to impairment
of the TLR3-dependent induction of type I IFN and IFN-l, result-
ing in predisposition to HSE. Autosomal dominant TRAF3
deficiency is the third genetic etiology of HSE to be identified,
after autosomal recessive UNC-93B deficiency (Casrouge
et al., 2006) and autosomal dominant TLR3 deficiency (Zhang
et al., 2007). It is a rare genetic etiology of HSE because no
TRAF3 coding mutations have been identified in 190 other
children with HSE analyzed. TRAF3 deficiency is also the first
primary immunodeficiency involving a TRAF protein to be identi-
fied. The presence of TRAF3 deficiency in a child with HSE
confirms the importance of an intact TLR3-IFN pathway for
controlling primary HSV-1 infection in the CNS (Zhang et al.,
2007). It further indicates that TLR3-mediated immunity is not
protective with only 10%–20% expression and function of
TRAF3. Mutations in the UNC93B1, TLR3, and TRAF3 genes
each affect only a small proportion of children with HSE. These
findings suggest that predisposition to HSE may result from
a collection of diverse, and possibly immunologically related,
single-gene defects (Alcais et al., 2009; Casanova and Abel,
2007; Alcais et al, 2010).
The patient with TRAF3 deficiency and HSE described here
is now 18 years old and has otherwise remained healthy off
any prophylaxis, with normal resistance to other infectious dis-
eases, including viral diseases in particular. Residual signaling
downstream from TLR3 is probably not involved in this resis-
tance, because UNC-93B-deficient patients have no detectable
residual TLR3 signaling but are nonetheless also resistant
to common viruses other than HSV-1. Antiviral IFN responses
triggered by receptors other than TLR3, whether TRAF3-depen-
dent (somewhat preserved because of the incomplete nature of
TRAF3 deficiency) or TRAF-3-independent (unaffected by the
TRAF3 defect), probably account for the normal resistance to
viruses observed in this TRAF3-deficient patient. With a single
18-year-old patient studied, it is obviously impossible to draw
firm conclusions regarding the range of infectious phenotypes
associated with dominant-negative TRAF3 alleles. Other infec-
tions may strike this patient later in life, and other patients
carrying dominant-negative TRAF3 alleles may display other
infectious phenotypes. Phenotypes other than infectious may
also occur. The TRAF3 defect also impairs signaling pathways
downstream from multiple TNF receptors. However, this broad
immunological phenotype has had so far no overt clinical conse-
quences. This may be transient because, for example, the
impairment of BAFF signaling might perhaps lead to disorders
of B cell immunity with increasing age (Warnatz et al., 2009).
In any case, the weak but detectable residual TRAF3-dependent
responses in this patient probably account for her survival into408 Immunity 33, 400–411, September 24, 2010 ª2010 Elsevier Inc.adulthood, contrasting with the neonatal death of mice with
complete TRAF3 deficiency (He et al., 2006; Xu et al., 1996).
In conclusion, this ‘‘experiment of nature’’ suggests that the first
apparent clinical consequence of decreases in TRAF3 produc-
tion and function is predisposition to HSE because of the
impairment of TLR3 responses.EXPERIMENTAL PROCEDURES
Human Molecular Genetics
We extracted RNA from Epstein-Barr virus-immortalized lymphoblastoid cell
lines (EBV-B cells) and immortalized fibroblast cell lines (SV40-fibroblasts),
using Trizol (Invitrogen, Carlsbad, California, USA), according to the manufac-
turer’s instructions. RNA was reverse-transcribed directly, with Oligo-dT
(Invitrogen). Polymerase chain reaction (PCR) was carried out with Taq
polymerase (Invitrogen), using the GeneAmp PCR System 9700 (Applied
Biosystems, Foster City, California, USA). The cDNA exons of TRAF3 were
amplified by PCR. The primer sequences used for the genomic coding region
of TRAF3 are as follows: forward primers: 1F, ggaccgcgagatgaggaa; 2F, gctcc
tggctccctactctt; 3F, taatgctgggacatctgctg; 4F, caactcgctcgaaaagaagg; 5F,
agccagcctttctacactgg; 6F, agtagctggggaggtggatt; and reverse primers: 1R,
cggtcagtgtgcagctttag; 2R, ctcgcaggtctttcctcaag; 3R, gcttggctgtctatcactcg;
4R, cgtccccgttcaggtagac; 5R, aaaacgtgtcaggtgtgctc; 6R, actgtatttgaaacaaa
attgcac.
The PCR products were purified by ultracentrifugation through Sephadex
G-50 Superfine resin (Amersham-Pharmacia-Biotech, Buckinghamshire, UK)
and sequenced with the BigDye Terminator Cycle Sequencing Kit (Applied
Biosystems). Sequencing products were purified by centrifugation through
Sephadex G-50 Superfine resin, and sequences were analyzed with an ABI
Prism 3700 apparatus (Applied Biosystems).
The mutation was confirmed by the analysis of genomic DNA extracted
from erythrocytes/granulocytes, EBV-B cells and SV40-fibroblasts. DNA was
isolated by phenol-chloroform extraction, as previously described (Giraffa
et al., 2000).
Multiple Amino Acid Sequence Alignment
The Homo sapiens TRAF3 (NP_003291.2) amino acid sequence was aligned
with other TRAF3 sequences by BLAST, using the protein database of the
National Center for Biotechnology Information website (NCBI, http://blast.
ncbi.nlm.nih.gov/Blast.cgi). Multiple sequence alignment was carried out
with CLUSTAL W (1.83), based on the TRAF3 amino acid sequences of Pan
troglodytes (XP_001164813), Macaca mulatta (XP_001082535.1), Equus
caballus (XP_001490050.1), Monodelphis domestica (XP_001367040.1),
Ornithorhynchus anatinus (XP_001507440.1), Mus musculus (NP_035762.2),
Sus scrofa (XP_001927435.1), Rattus norvegicus (NP_001102194.1), Bos
taurus (XP_582595.3), Canis familiaris (XP_547989.2), Gallus gallus
(XP_421378.1), Oncorhynchus mykiss (XP_001507398.1), and Danio rerio
(NP_001003513.1).
Cell Purification and Culture
Freshly isolated human peripheral blood mononuclear cells (PBMC) were
isolated by Ficoll-Hypaque density gradient centrifugation (Amersham-Phar-
macia-Biotech) from cytopheresis or whole-blood samples obtained from
patients or healthy volunteers. PBMCs were stimulated for 40 hr, at a density
of 23 106 cells/ml, in RPMI 1640 (Invitrogen) supplemented with 10% fetal calf
serum (FCS) (Invitrogen).
Primary human fibroblasts were obtained from biopsies of patients or
healthy controls and were cultured in DMEM (Invitrogen) supplemented with
10% FCS. They were then transformed with an SV40 vector, as previously
described (Chapgier et al., 2006), to create immortalized fibroblast cell lines:
SV40-fibroblasts. The SV40-fibroblast cell lines were activated in 24-well
plates, at a density of 105 cells/well, for 24 hr (or 2, 10, and 24 hr in the poly
(I:C) kinetic studies).
EBV-B cell lines were obtained from patients and normal donors as previ-
ously described (Pellat-Deceunynck et al., 1999). BAFFR/ EBV-B cells
were kindly provided by Klaus Warnatz, PhD. EBV-B cells were cultured in
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plates, at a density of 5 3 106 cells/well, for 24 hr.
For the differentiation and culture of monocyte-derived dendritic cells
(MDDCs), PBMCs freshly isolated by Ficoll-Hypaque density gradient
centrifugation from healthy controls and patients were incubated in RPMI
1640 supplemented with 10% FCS in cell culture flasks for 1 hr at 37C under
an atmosphere containing 5% CO2. The adherent cells (monocytes) were
cultured for 8 days in RPMI 1640 supplementedwith 10%FCS, in the presence
of GM-CSF (R&D Systems, Minneapolis, MN, USA, 50 ng/ml) and IL-4 (R&D
Systems, 10 ng/ml). The differentiation and purity of these cells were
confirmed by staining with antibodies directed against CD1a (PE, BD PharMin-
gen, San Diego, CA, USA) and CD14 (FITC, Becton Dickinson) or a conjugated
mouse IgG1 isotype control (PE or FITC, Becton Dickinson). Stained cells were
analyzed by flow cytometry (FACSCanto flow cytometer, Becton Dickinson).
For stimulation, the cells were plated at a density of 0.25 3 105 cells/well in
48-well tissue culture plates and cultured in the presence of GM-CSF and
IL-4; MDDCs were stimulated for 24 hr.
For the differentiation and culture of monocyte-derived macrophages
(MDM), PBMCs freshly isolated by Ficoll-Hypaque density gradient centrifuga-
tion from healthy controls and patients were incubated in RPMI 1640
supplemented with 10% FCS, in cell culture flasks, for 1 hr, at 37C, under
an atmosphere containing 5% CO2. The adherent cells (monocytes) were
cultured for 10 days in RPMI 1640 supplemented with 10% FCS, in the
presence of Rh-M-CSF (R&D Systems, 10 mg/ml). For stimulation, the cells
were plated at a density of 0.253 105 cells/well in 96-well tissue culture plates
and stimulated for 24 hr.
All cells were grown at 37C, under an atmosphere containing 5% CO2.
Determination of mRNA levels by Q-PCR
Total RNA was extracted from EBV-B cells, SV40-fibroblasts RAW, and
RAWTRAF3/ cells, untransfected or transfected. In some cases, the cells
were stimulated with 25 mg/ml poly(I:C) (InvivoGen, San Diego, CA, USA) for
4 hr. RNA was reverse-transcribed directly, using Oligo-dT, to determine
TRAF3, IFN-b, and IFN-l mRNA levels. The b-glucuronidase (GUS) or 18S
rRNA gene was used for normalization. Quantitative real-time PCR (Q-PCR)
was performed with Applied Biosystems Assays-on-Demand probe/primer
combinations and 23 universal reaction mixture, in an ABI PRISM 7700
Sequence Detection System. Results are expressed using the DDCt method,
as described by the manufacturer.
Immunoblots
Total cell extracts were prepared from SV40-fibroblasts, EBV-B cells, and
RAW and RAW-TRAF3/ cells, either not transfected or stably transfected
with pWPI, pWPI-TRAF3, pBABE, or pBABE-TRAF3-R118W. In some cases,
SV40-fibroblasts were activated by incubation with 25 mg/ml poly(I:C) for
24 hr. Equal amounts of protein from each sample were separated by
SDS-PAGE and blotted onto iBlot Gel Transfer Stacks (Invitrogen). These
nitrocellulose membranes were then probed with anti-TRAF3 polyclonal
antibody (Abcam, Cambridge, MA, USA) or anti-NF-kB2 p100/p52 (18D10)
rabbit mAb (human specific) (Cell Signaling, Beverly, MA, USA), followed
by a secondary horseradish-conjugated donkey anti-rabbit IgG (GE Health-
care, Buckinghamshire, UK). Membranes were stripped and reprobed with
an antibody against GADPH (Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA), to control for protein loading. Antibody binding was detected
by enhanced chemiluminescence (ECL; Amersham-Pharmacia-Biotech).
Antibody-2 is an anti-TRAF3 polyclonal antibody (Cell Signaling Technology).
Stimulations
We used the following Toll-like receptor (TLR) agonists: a synthetic analog
of dsRNA, polyinosinepolycytidylic acid (poly(I:C), a TLR-3 agonist, at a
concentration of 25 mg/ml); lipopolysaccharide (LPS Re 595 from Salmonella
minnesota, a TLR-4 agonist, at 10 mg/ml; Sigma, St Louis, MO, USA); resiqui-
mod hydrochloride (R-848, a TLR-7 and -8 agonist, at 3 mg/ml; GLSynthesis
Inc., Worcester, MA, USA); IL-1b (at 20 ng/ml; R&D Systems Inc.); TNF-a (at
20 ng/ml; R&D Systems Inc.). All agonists and reagents were endotoxin-free.
For all stimulations of PBMCs with TLR agonists other than LPS, cells were
incubated with polymyxin B (10 mg/ml) (Sigma) at 37C, for 30 min before
activation.ImFor RIG-I/MDA5 stimulation, we used 0.25 mg of poly(I:C) or 0.1 mg of
noncoding RNA (7sk-as), kindly provided by Caetano Reis e Sousa
(Pichlmair et al., 2006), and carried out transfection with Lipofectamine
Reagent (Invitrogen), according to the kit manufacturer’s instructions.
LTa1b2 (R&D Systems, 65 ng/ml) was used to activate lymphotoxin-
b receptor (LTbR), with or without IFN-g (Imukin; Boehringer Ingelheim, Ingel-
heim, Germany), at a concentration of 80 IU/ml. B cell-activating factor
receptor (BAFF-R) was activated with human BAFF (Miltenyi Biotec, Bergisch
Gladbach, Germany) at a concentration of 100 ng/ml.
For viral stimulation, we used the following: (1) dsDNA viruses: herpes
simplex virus-1 (HSV-1, strain KOS-1, multiplicity of infection [MOI] = 1);
HSV-1 inactivated by ultraviolet (UV) radiation (HSV-1i); BK virus (BKV, an
isolate from a patient, provided by Pierre Lebon, Paris, France, MOI = 0.02).
(2) ss()RNA viruses: vesicular stomatitis virus (VSV, strain Indiana, MOI = 1),
Newcastle disease virus (NDV, strain BR24 444, MOI = 0.5), measles virus
(measles V, strain Edmonston, MOI = 0.004), Sendai virus (Sendai V, strain
E92, MOI = 12.5), parainfluenza virus III (para-III, strain EA102, MOI = 0.04),
mumps virus (mumps V, vaccine strain Urabe, MOI = 0.04). (3) ss(+)RNA
viruses: sindbis virus (sindbis V, strain VR1248 ATCC, MOI = 0.2), encephalo-
myocarditis virus (EMCV, MOI = 0.1).
In some experiments, cells were treated with IFN-a (intron A, Schering-
Plough, Kenilworth, NJ, USA) at a concentration of 105 IU/ml before
stimulation. CD40 was activated in MDDC, as previously described (Filipe-
Santos et al., 2006). In EBV-B cells, CD40 was activated with soluble human
MegaCD40L (ENZO Life Science Inc., Farmingdale, NY, USA) at a concentra-
tion of 2 mg/ml.
Cell supernatants were recovered and their cytokine concentrations
determined by ELISA.
Cytokine Determinations
The production of IFN-a, -b, -l, IL-6, IL-8, IL-10, IL-12p40, and TNF-a was
assessed by ELISA. An ELISA was carried out for each of IFN-a (AbCys SA,
Paris, France), IFN-b (TFB, Fujirebio, Inc., Tokyo, Japan), IL-6, IL-8, IL-10,
TNF-a (Sanquin, Amsterdam, Holland), IL-12p40, and mouse IFN-b (R&D
Systems), according to the kit manufacturer’s instructions. The ELISA for
IFN-l was carried out as previously described (Zhang et al., 2007).
Signal Transduction Studies in SV40 Fibroblasts
Cell nuclear extracts were prepared from SV40 fibroblasts, following incuba-
tion with or without Poly(I:C), TNF-a, and IL-lb. NF-kB ELISA (Active Motif,
Calrsbad, CA, USA) was carried out according to the kit manufacturer’s
instructions.
For the detection of IRF-3 dimerization, whole-cell extracts were prepared
from SV40-fibroblasts with or without Poly(I:C) (25 mg/ml) treatment for 1 or
2 hr. The IRF-3 monomers and dimers were separated by native PAGE in
the presence of 1% sodium deoxycholate (DOC) (Sigma). Total cell extracts
(50 mg of protein) were diluted 1:5 in nondenaturing sample buffer
(312.5 mM Tris–HCl, pH 6.8, 50% glycerol, 0.05% bromophenol blue and
5% DOC) and separated by electrophoresis in a 7.5% polyacrylamide gel, in
25 mM Tris and 192 mM glycine, pH 8.4, with 1% DOC present in the cathode
chamber only. The gel was blotted onto a membrane, which was then probed
with the anti-IRF-3 antibody (FL-425, Santa Cruz Biotechnology) followed by
a secondary horseradish-conjugated anti-rabbit IgG.
Cell Viability Assay
The viability of SV40-fibroblasts was assessed by resazurin oxidoreduction
(TOX-8) (Sigma). Cells were plated, in triplicate, in 96-well flat-bottomed plates
(2 3 104 cells/well), in DMEM supplemented with 2% FCS; 24 hr later, cells
were infected by incubation for 24 hr with VSV at the indicated multiplicity of
infection (MOI). Resazurin dye solution was then added (5 ml per well) to the
culture medium, and the samples were incubated for an additional 2 hours
at 37C. Fluorescence was then measured at a wavelength of 590 nm, using
an excitation wavelength of 531 nm. Background fluorescence, calculated
for dye and complete medium alone (in the absence of cells), was then
subtracted from the values for all the other samples: 100% viability corre-
sponds to the fluorescence of uninfected cells. For assays of cell protection
upon viral stimulation, cells were treated with IFN-a (105 IU/ml) for 24 hr before
infection and during infection.munity 33, 400–411, September 24, 2010 ª2010 Elsevier Inc. 409
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For viral infection, 105 SV40-fibroblasts were plated in individual wells of
24-well plates and infected, at a MOI of 10, in DMEM supplemented with
2% FCS. The Stat-1-deficient patient studied has been described elsewhere.
After 30min, cells were washed and incubated in 500 ml of medium. The super-
natants were frozen at the time points indicated in the figures. Viral titers were
determined by calculating the 50% tissue culture infectious dose (TCID50), as
described by Reed and Muench, after the inoculation of Vero cell cultures in
96-well plates. For assays of cell protection upon viral stimulation, cells were
treated with IFN-a (105 IU/ml) for 18 hr before infection, as appropriate.
Determination of Cell Death via the LTbR Pathway
We assessed levels of SV40-fibroblast cell death via the LTbR pathway by
TOX-8 assays. Cells were plated, in triplicate, in 96-well flat-bottomed plates
(2 3 104 cells/well), in DMEM supplemented with 2% FCS; 24 hr later, cells
were treated with LTa1b2 (65 or 100 ng/ml), with or without IFN-g at a concen-
tration of 80 IU/ml and incubated for 72 hr. Resazurin dye solution was then
added (5 ml per well) to the culture medium, and the samples were incubated
for an additional 2 hours at 37C. Fluorescence was then measured at a
wavelength of 590 nm, using an excitation wavelength of 531 nm. Background
fluorescence, calculated for dye and complete medium alone (in the absence
of cells), was then subtracted from the values for all the other samples: 100%
viability corresponds to the fluorescence of nonstimulated cells.
Site-Directed Mutagenesis and Cloning
Site-directed mutagenesis was performed with QuikChange II XL (Stratagene,
La Jolla, CA, USA), using the pCR4.0-TRAF3 plasmid (kindly provided by
Jonathan Keats, PhD). The TRAF3-R118W gene generated by mutagenesis
was inserted into the pBABE-puro expression vector (Addgene, Cambridge,
MA, USA) (pBABE-TRAF3-R118W).
Two TRAF3 C-terminal deletions without amino acids 289–568 were created
in the pBABE-puro expression vector: (1) pBABE-TRAF3-D(289-568) and (2)
pBABE-TRAF3-R118W-D(289-568).
Stable Transfections
Cells (SV40-fibroblasts, RAW and RAW-TRAF3/ cells [kindly provided by
Michael Karin, PhD]) were transfected by electroporation at 250 V and
960 mF, in phosphate-buffered saline (107 cells/ 0.5 ml). We used 5 mg of
pWPI-TRAF3 (kindly provided by Jonathan Keats, PhD) or pBABE-TRAF3-
R118W, linearized with FspI (New England Biolabs, Beverly, MA, USA), for
transfection. Transfectants were selected by sorting cells expressing green
fluorescent protein (GFP) for pWPI-TRAF3, or in 0.5 mg/ml puromycin 24 hr
after electroporation for pBABE-TRAF3-R118W. The presence of TRAF3
was checked by Q-PCR and immunoblotting. The same conditions were
used for the transfection of cells with mock vectors.
Transient Transfections
RAW and RAW-TRAF3/ cells were transfected with 2 mg of plasmid (all
derived from the pBABE-puro expression vector) at various ratios, in the
presence of the FuGENE HD Transfection Reagent (Roche Applied Science,
Indianapolis, IN, USA), according to the kit manufacturer’s instructions.
SUPPLEMENTAL INFORMATION
Supplemental Information contains a Supplemental Note and six figures and
can be found online at doi:10.1016/j.immuni.2010.08.014.
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